Clinical Research Directory

Inclusion Criteria: * Willing to provide informed consent. * Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned. * Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy. * Individuals at least 18 years of age. * Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study. * Willing to comply with all study procedures and be available for the duration of the study. Exclusion Criteria: * Not able to receive treatment with ICI therapy * Use of investigational drugs, biologics, or devices within 30 days prior to enrollment. * Women who are pregnant, lactating, or planning on becoming pregnant during the study. * Not suitable for study participation due to other reasons at the discretion of the investigators.